Docket Number:11A-970730
Inventor:Chun-Hung Lin, Ching-Wen Ho
IP Status:US Provisional
Abstract:
Human glycosidases usually exist as multiple and functionally related enzymes. The promiscuity of many inhibitors and the resultant inhibition of multiple enzymes render them of limited utility in studying the cellular and organismal physiological role of one particular enzyme due to formation of generate complex phenotypes. Therefore generation of selective inhibitors of a specific glycosidase can reduce undesired side effect on functionally related enzymes.
Hexosaminidase is the dominant glycosyaminoglycan-degrading glycosidase released by the chrondrocytes into the extracellular compartment, and is the dominant glycosidase in synovial fluid from patients with osteoarthritis. Inhibitors of this enzyme has been shown to prevent or even to reverse cartilage degradation.
Hexosaminidase is also linked to GM2 gangliosidosis, a family of lysosomal storage disorders characterized by the intralysosomal accumulation of glycolipid GM2 ganglioside. Tay-Sachs disease and Sandhoff disease arise from mutations of the hexosaminidase genes (hexa and hexb, respectively). Enzyme inhibitors have been shown to serve as pharmacological chaperones (or chemical chaperones) to increase the stability of defective lysosomal enzymes and thus to maintain a minimum level of their metabolic functions.
Hexosaminidase and O-GlcNAcase catalyze the hydrolytic cleavage of terminal N-acetylglucosamine residues from glycoconjugates. Both enzymes share a common catalytic mechanism. In order to develop effective therapeutic intervention with a minimal side effect, it is necessary to develop potent inhibitors of great selectivity. At the current stage, the development of O-GlcNAcase inhibitors have been well established to reach great inhibition potency and selectiveity. But the progress to develop hexosaminidase inhibitors is limited. We report herein the discovery of potent and selective N-acetyl-b-hexosaminidase (Hex) inhibitors. The best one gave KI of 0.69 nM against human HEX with selectivity of 19000 over a similar enzyme O-GlcNAcase. The molecules were shown not only to target lysosomal HEX, but also to modulate intracellular ganglioside GM2 levels according to the immuno-fluorescence and -precipitation studies.
Because the molecule only inhibits the similar enzyme O-GlcNAcase at KI of microM range, the great selectivity offers a great potential for further development of therapeutic agents.
Contact Person:
對本技術有興趣,請於本處網頁廠商選項下(廠商需求與諮詢)網頁填寫資料,承辦人將跟您聯絡。
If you are interested in this technology, please fill in the information on the webpage under the manufacturer option (Apply for Technology Licensing, Material Transfer, or Sponsored Research) on the website of this office, and the undertaker will contact you.
